|
Gender, n (%)
|
|
Female
|
203 (66.1%)
|
|
Age (years), mean (SD)
|
65.1 (12.5)
|
|
range
|
23.0–94.0
|
|
Personal situation, n (%)
|
|
Living alone at home
|
58 (18.9%)
|
|
Living with other at home
|
248 (80.8%)
|
|
Living in assisted living environment
|
1 (0.3%)
|
|
Other
|
0 (0.0%)
|
|
Education, n (%)
|
|
CGSE/O level
|
97 (31.6%)
|
|
A Level or equivalent
|
60 (19.5%)
|
|
Undergraduate degree
|
36 (11.7%)
|
|
Post-graduate
|
31 (10.1%)
|
|
Other
|
83 (27.0%)
|
|
Professional status, n (%)
|
|
Full time paid employment
|
61 (19.9%)
|
|
Part time work
|
43 (14.0%)
|
|
Homemaker/housewife
|
17 (5.5%)
|
|
Student
|
1 (0.3%)
|
|
Unemployed
|
4 (1.3%)
|
|
Retired
|
171 (55.7%)
|
|
Other
|
10 (3.3%)
|
|
Time from diagnosis to questionnaire completion (years), mean (SD)
|
12.3 (9.8)
|
|
range
|
0.5–56.7
|
|
Use of at least one RA treatment other than MTX, n (%)
|
|
Yes
|
220 (71.7%)
|
|
No
|
87 (28.3%)
|
|
Presence of comorbidities, n (%)
|
|
Yes
|
133 (43.3%)
|
|
No
|
174 (56.7%)
|
|
Time between first dose of MTX and questionnaire completion, n (%)
|
|
Less than a year
|
6 (2.0%)
|
|
From 1 to less than 5 years
|
94 (30.6%)
|
|
From 5 to less than 10 years
|
99 (32.2%)
|
|
10 years or more
|
108 (35.2%)
|
|
Weekly MTX dosage (mg), mean (SD)
|
15.7 (5.4)
|
|
range
|
5.0–30.0
|
|
6-month PDC < 80%, n(%)
|
89 (29.0%)
|
|
12-month PDC < 80%, n(%)
|
85 (27.7%)
|
|
ACCEPT General Acceptance Score, mean (SD)
|
74.2 (27.5)
|
|
range
|
0.0–100
|
|
RAPID-3 Total Score, mean (SD)
|
9.3 (5.9)
|
|
range
|
0.0–25.7
|
